Xeris Pharmaceuticals | XERS - Current Assets


Xeris Pharmaceuticals reported $224.02M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Celltrion KRW 5.54T 291.68B Sep/2025
Cspc Pharmaceutical CNY 22.61B 721.94M Jun/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 413.82M 150.22M Sep/2025
Divis Laboratories Ltd INR 98.43B 2.38B Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Kangmei Pharma CNY 7.03B 128.34M Sep/2025
Knight Therapeutics CAD 397.57M 36.96M Sep/2024
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 35.54M 2.13M Jun/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neuren Pharmaceuticals AUD 320.25M 79.08M Jun/2025
Organigram Holdings CAD 284.9M 7.11M Sep/2025
Ovoca Bio EUR 4.96M 2.06M Jun/2022
Pacira USD 562.75M 182.86M Sep/2025
Perrigo USD 2.88B 264.2M Sep/2025
Pharma Mar EUR 242.88M 6.52M Sep/2025
Qiagen NV USD 2B 535.87M Dec/2025
Sartorius EUR 1.72B 449M Sep/2025
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Supernus Pharmaceuticals USD 593.89M 144.98M Sep/2025
Tilray USD 688.63M 2.34M Mar/2025
Zz Pientze Pharmaceu CNY 10.7B 1.59B Sep/2025